- Home
- RLMD vs BLRX Comparison
RLMD vs BLRX Comparison
Compare RLMD & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- BLRX
- Stock Information
- Founded
- RLMD 2004
- BLRX 2003
- Country
- RLMD United States
- BLRX Israel
- Employees
- RLMD N/A
- BLRX N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- BLRX Health Care
- Exchange
- RLMD Nasdaq
- BLRX Nasdaq
- Market Cap
- RLMD 11.5M
- BLRX 12.2M
- IPO Year
- RLMD N/A
- BLRX 2011
- Fundamental
- Price
- RLMD $0.30
- BLRX $3.10
- Analyst Decision
- RLMD Hold
- BLRX Buy
- Analyst Count
- RLMD 4
- BLRX 2
- Target Price
- RLMD $4.25
- BLRX $26.00
- AVG Volume (30 Days)
- RLMD 382.7K
- BLRX 26.4K
- Earning Date
- RLMD 03-27-2025
- BLRX 05-27-2025
- Dividend Yield
- RLMD N/A
- BLRX N/A
- EPS Growth
- RLMD N/A
- BLRX N/A
- EPS
- RLMD N/A
- BLRX N/A
- Revenue
- RLMD N/A
- BLRX $28,940,000.00
- Revenue This Year
- RLMD N/A
- BLRX N/A
- Revenue Next Year
- RLMD N/A
- BLRX N/A
- P/E Ratio
- RLMD N/A
- BLRX N/A
- Revenue Growth
- RLMD N/A
- BLRX 502.92
- 52 Week Low
- RLMD $0.24
- BLRX $2.85
- 52 Week High
- RLMD $5.09
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- RLMD 50.05
- BLRX 41.70
- Support Level
- RLMD $0.26
- BLRX $3.01
- Resistance Level
- RLMD $0.32
- BLRX $3.61
- Average True Range (ATR)
- RLMD 0.02
- BLRX 0.22
- MACD
- RLMD 0.00
- BLRX 0.02
- Stochastic Oscillator
- RLMD 67.34
- BLRX 32.89
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.